Publications and Articles

Welcome to Publications and Articles in Aphios Corporation Resource Center, your source for information on Aphios' therapeutic products and enabling technology platforms.

We have authored a few patents and some articles which have been featured in a number of industry journals and magazines. We invite you to read through the articles of interest to you. Articles are added as they become available, so check back periodically to read the latest additions.

"Acute Oral Bryostatin-1 Administration Improves Learning Deficits in the APP/PS1 Transgenic Mouse Model of Alzheimer's Disease" -  Current Alzheimer Research, 2015, 12, 22-31 (528 KB) Previous studies showed that Bryostatin-1, a potent PKC modulator and alpha-secretase activator, can improve cognition in models of Alzheimer's disease (AD) with chronic (>10 weeks), ..... more >

"Nanotechnology 101" - MedTech Boston, December 2, 2014 (201 KB) One of the companies at the forefront in tackling drug delivery problems is the Woburn, Massachusetts-based Aphios, which holds a new patent on polymer nanospheres, formed using proprietary supercritical fluid technology, to enhance solubility of poorly soluble drugs.... more >

"Hope that a prescription can mimic marijuana's benefits" - The Boston Globe, November 17, 2014 (261 KB) While marijuana is made up of hundreds of chemicals, CBD holds a special lure for scientists. Unlike THC, the ingredient that causes marijuana's "high," CBD is nonpsychoactive, and patient stories abound about CBD-rich marijuana strains calming seizures..... more >

"Inspired by nature, enabled by science" - Biopharma Deal Makers, Nature Publishing Group, November 1, 2014 Aphios is using environmentally sustainable technologies to develop and deliver safe and effective drugs for the prevention and treatment of disease, including CNS disorders such as Alzheimer's disease and multiple sclerosis, cancer and infectious diseases..... more >

"Cannabis-Based Pharmaceuticals: The Next Frontier?" – Life Science Leader, October 30 2014 (132 KB) Unlike medical marijuana companies, biopharmaceutical companies, including GW Pharma, Kannalife Sciences, Aphios, and others, are committed to developing cannabis-derived pharmaceuticals using conventional U.S. FDA regulatory approval pathways..... more >

"Green, Enabling Technology Platforms for Drug Discovery, Nanotechnology Drug Delivery And Manufacturing Improvement" - CEOCFO Magazine, June 9, 2014 issue (97.8 KB) "As the company evolved we realized that in order to solve some of the problems that we have with cancer and aging, such as Alzheimer's disease, we have to look to nature and marine organisms and terrestrial plants, which often live for thousands of .... more >

"Pretreating Cellulosic Biomass" - BioPlastics Magazine, 2014, Vol. 9, p. 6 (820 kB) Aphios Corporation of Woburn, Massachusetts, USA recently today announced that it was granted a US patent for its cellulosic biomass pretreatment technology platform [Aosic]. Celluosic biomass resources are currently greatly underutilized around the world .... more >

"Amylon Spins Out To Explore Tau Third Alternative in AD" – BioWorld Today, Volume 24, Number 230, December 2013, p. 1-6 (576 KB) Amylon LLC, a spinout of Aphios Corp., is prepared to tilt at the windmill that is Alzheimer's disease through a chemical pathway that has defeated numerous previous attempts, including drugs from industry giant Eli Lilly and Co. There are three critical enzymes .... more >

"Bryostatin-1 vs. TPPB: Dose-Dependent APP Processing and PKC-α, -δ, and -ε Isoform Activation in SH-SY5Y Neuronal Cells" - Journal of Molecular Neuroscience, Published Online June 15, 2012 (365 KB) Activation of the α-secretase processing pathway of amyloid precursor protein (APP) is recognized as an important mechanism which diverts APP processing from production of beta-amyloid (Aβ) to ..... more >

"Bryostatin-1 Synergizes with Histone Deacetylase Inhibitors to Reactivate HIV-1 from Latency" – Current HIV Research, Volume 8, Number 6, September 2010, p. 418-429 (2.07 MB) The persistence of latent HIV-infected cellular reservoirs represents the major hurdle to virus eradication on patients treated with HAART. It has been suggested that successful depletion of such latent reservoirs will require a combination of therapeutic agents that.... more >

"Polymer Nanospheres for Improved Drug Delivery of Protein Therapeutics and Viral Antigens" - Technical Proceedings of the 2007 NSTI Nanotechnology Conference and Trade Show, 2007, Vol. 2, 362-365 (355.27 KB) Biologically adherent polymeric microsphere carriers have been shown to be effective in the oral delivery of proteins such as insulin and DNA plasmids. These microspheres are comprised of hydrophobic copolymers that appear to have a significantly longer.... more >

"Phospholipid Nanosomes" - Current Drug Delivery, 2005, Vol. 2, No. 4 (468.17 KB) Phospholipid nanosomes are small, uniform liposomes manufactured utilizing supercritical fluid technologies. Supercritical fluids are first used to solvate phospholipid raw materials, and then decompressed to form phospholipid nanosomes that can.... more >

"Protein Nanoparticles" - Technical Proceedings of the 2005 NSTI Nanotechnology Conference and Trade Show, 2005, Vol. 1, 172-175 (308.49 KB) Protein nanoparticles can be utilized for the pulmonary delivery of protein therapeutics or can be incorporated into biodegradable polymer microspheres/nanospheres for controlled release depot or oral delivery. With proteinaceous therapeutics, the generation of.... more >

"Nature's Way: The Case For, Against Natural Therapeutics" – Mass High Tech, Apr. 15, 2004 Arguing the case for and against natural therapeutics is like arguing the case for and against food, oxygen and water. These are all necessary for our very existence, yet all must be taken in moderation and balance. Out of proportion, we can be readily.... more >